Novel Biomarkers in Alzheimer's Disease

• Autore: Villa Chiara
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
• Descrizione fisica: 1 online resource (442 p.)
• Soggetto topico: Medicine and Nursing
• Soggetto non controllato: (18F)FDG; adipose tissue dysfunction; ageing; aging; Alzheimer disease; Alzheimer's disease; Alzheimer's disease (AD); amyloid; amyloid beta; Amyloid Beta; amyloid beta peptide; amyloid cascade hypothesis; antioxidant; ApoE; APOE; APOE alleles; APP mutations; bacteria; behavioral and psychological symptoms of dementia (BPSD); beta-amyloid; biofluids; biomarker; biomarkers; blood; cardiovascular risk factors; carotenoids; CART analysis; cerebrospinal fluid; clinical trials; Clock; clock genes; cognition; cognitive decline; COMT; cytokines; dementia; diabetes; diagnosis; diagnostic research; diagnostics; drug development; early diagnosis; early onset AD; EEG; endophenotypes; energetic metabolism; episodic memory; exosomes; familial AD; flotillin; genetic variants; genetics of AD; germline mutations; glucose metabolism; glycolytic reserve; inflammation; late onset AD; lysosomes dysfunction; membrane potential; messenger RNA; metabolomics; microRNA; mild cognitive impairment; mitochondrial; mitochondrial dysfunction; mitochondrial spare respiratory capacity; MTHFR; Multiplex; multivariate analysis; n/a; neurodegeneration; neurofilament light chain; neuroimaging; neuroinflammation; neuropsychiatry inventory scale (NPI); neuropsychological assessment; neuropsychology; neurotropic microbes; NfL; nutrition; obesity; older adults; omega-3 fatty acids; person-tailored; PET/CT; phonemic fluency; phosphorylated tau; physical performance; precision medicine; prognostics; PSEN1; PSEN2; semantic memory; semantic priming; SiMoA; soluble TREM2; subjective cognitive decline; synaptic biomarkers; tau; Tau; TMS; total tau; Type-3-Diabetes; virus; vitamin E
• Persona (resp. second.): VillaChiara
• Sommario/riassunto: Alzheimer's disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD.
• Titolo autorizzato: Novel Biomarkers in Alzheimer's Disease
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557129403321
• Lo trovi qui: Univ. Federico II